[:en]FDA Approves Nivolumab Plus Ipilimumab for the First-Line Treatment of Unresectable Malignant Pleural Mesothelioma[:] News [:en]FDA Approves Nivolumab Plus Ipilimumab for the First-Line Treatment of Unresectable Malignant Pleural Mesothelioma[:] By Zalika Famaceutica|2022-09-10T18:10:53-03:00October 6, 2020|News|